{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:30:51Z","timestamp":1793496651171,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.annonc.2025.07.007","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T23:53:24Z","timestamp":1753142004000},"page":"1299-1306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cancer of unknown primary site and TNM staging: a new paradigm for patient management"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2802-3741","authenticated-orcid":false,"given":"F.","family":"Anthony Greco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2025.07.007_bib1","series-title":"UpToDate","article-title":"Adenocarcinoma of unknown primary site","author":"Hainsworth","year":"2024"},{"key":"10.1016\/j.annonc.2025.07.007_bib3","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.ejca.2007.06.023","article-title":"Switching benchmarks in cancer of unknown primary from autopsy to microarray","volume":"43","author":"Pentheroudakis","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2025.07.007_bib4","article-title":"Cancer of unknown primary site. A new era of practice-changing approaches to diagnosis, staging, and precision therapy","volume":"1","author":"Greco","year":"2024","journal-title":"JCO Oncol Adv"},{"key":"10.1016\/j.annonc.2025.07.007_bib5","series-title":"AJCC Cancer Staging Manual","year":"2002"},{"key":"10.1016\/j.annonc.2025.07.007_bib6","series-title":"AJCC Cancer Staging Manual","year":"2009"},{"key":"10.1016\/j.annonc.2025.07.007_bib7","series-title":"AJCC Cancer Staging Manual","year":"2018"},{"key":"10.1016\/j.annonc.2025.07.007_bib8","series-title":"AJCC Cancer Staging Manual","first-page":"3","article-title":"Principles of cancer staging","author":"Gress","year":"2018"},{"key":"10.1016\/j.annonc.2025.07.007_bib9","series-title":"AJCC Cancer Staging Manual","first-page":"589","article-title":"Breast","author":"Hortobagyi","year":"2018"},{"key":"10.1016\/j.annonc.2025.07.007_bib10","series-title":"AJCC Cancer Staging Manual","first-page":"103","article-title":"Nasopharynx","author":"Lee","year":"2018"},{"key":"10.1016\/j.annonc.2025.07.007_bib11","series-title":"AJCC Cancer Staging Manual","first-page":"113","article-title":"HPV-mediated (p16) oropharyngeal cancer","author":"O\u2019Sullivan","year":"2018"},{"key":"10.1016\/j.annonc.2025.07.007_bib12","series-title":"AJCC Cancer Staging Manual","first-page":"67","article-title":"Cervical lymph nodes and unknown primary tumors of the head and neck","author":"Patel","year":"2018"},{"key":"10.1016\/j.annonc.2025.07.007_bib13","series-title":"AJCC Cancer Staging Manual","first-page":"563","article-title":"Melanoma of the skin","author":"Gershenwald","year":"2018"},{"key":"10.1016\/j.annonc.2025.07.007_bib14","series-title":"UpToDate","article-title":"Axillary node metastasis with occult primary breast cancer","author":"Kaklamani","year":"2025"},{"key":"10.1016\/j.annonc.2025.07.007_bib15","series-title":"UpToDate","article-title":"Head and neck squamous cell carcinoma of unknown primary","author":"Saltman","year":"2023"},{"key":"10.1016\/j.annonc.2025.07.007_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.seminoncol.2008.10.009","article-title":"Pathologic evaluation of unknown primary cancer","volume":"36","author":"Oien","year":"2009","journal-title":"Semin Oncol"},{"key":"10.1016\/j.annonc.2025.07.007_bib18","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/PAP.0000000000000256","article-title":"An algorithmic immunohistochemical approach to define tumor type and assign site of origin","volume":"27","author":"Bellizzi","year":"2020","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.annonc.2025.07.007_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40291-015-0133-8","article-title":"Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay","volume":"19","author":"Greco","year":"2015","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.annonc.2025.07.007_bib20","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/jnci\/djt099","article-title":"Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology","volume":"105","author":"Greco","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.annonc.2025.07.007_bib21","article-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Occult Primary","year":"22024","journal-title":"Cancer of unknown primary (CUP)"},{"key":"10.1016\/j.annonc.2025.07.007_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1476-4598-12-57","article-title":"Novel microRNA-based array demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary","volume":"12","author":"Pentheroudakis","year":"2013","journal-title":"Mol Cancer"},{"key":"10.1016\/j.annonc.2025.07.007_bib23","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00428-014-1545-2","article-title":"Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care","volume":"464","author":"Hainsworth","year":"2014","journal-title":"Virchows Arch"},{"key":"10.1016\/j.annonc.2025.07.007_bib24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/EDBK_100014","article-title":"Cancer of unknown primary site: new treatment paradigms in the era of precision medicine","author":"Hainsworth","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.annonc.2025.07.007_bib25","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(16)30297-2","article-title":"Epigenetic profiling to classify cancer of unknown primary. A multicenter, retrospective analysis","volume":"17","author":"Moran","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2025.07.007_bib26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12967-022-03318-6","article-title":"Clinical validation of a 90-gene expression test for tumor tissue of origin diagnosis: a large-scale multicenter study of 1417 patients","volume":"20","author":"Sun","year":"2022","journal-title":"J Transl Med"},{"issue":"suppl 2","key":"10.1016\/j.annonc.2025.07.007_bib27","article-title":"mLBAlO0 CUP-ONE trial: a prospective double-blind validation of a molecular classifier assay in the diagnosis of cancer of unknown primary and clinical outcomes","volume":"34","author":"Wasan","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.07.007_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101016","article-title":"Machine learning analysis using 77,0447 genomic and transcriptomic profiles to accurately predict tumor type","volume":"14","author":"Abraham","year":"2021","journal-title":"Transl Oncol"},{"key":"10.1016\/j.annonc.2025.07.007_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2597","article-title":"Application of a neural network whole transcriptome-based pan-cancer method for diagnosis of primary and metastatic cancers","volume":"2","author":"Grewal","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.annonc.2025.07.007_bib30","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1158\/0008-5472.CAN-17-0628","article-title":"Utility of genomic analysis in circulating tumor DNA from patients with carcinoma of unknown primary","volume":"77","author":"Kato","year":"2017","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.annonc.2025.07.007_bib31","doi-asserted-by":"crossref","first-page":"bbae028","DOI":"10.1093\/bib\/bbae028","article-title":"New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges","volume":"25","author":"Ma","year":"2024","journal-title":"Brief Bioinform"},{"issue":"1","key":"10.1016\/j.annonc.2025.07.007_bib32","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1038\/s41467-024-47195-7","article-title":"A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary","volume":"15","author":"Conway","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2025.07.007_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101092","article-title":"The need for validation of MI GPSai in patients with CUP: Comment on; \u201cMachine learning analysis using 70,044 genomic and transcriptomic profiles to accurately predict tumor type\u201d by J Abraham et al","volume":"14","author":"Greco","year":"2021","journal-title":"Transl Oncol"},{"key":"10.1016\/j.annonc.2025.07.007_bib34","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jamaoncol.2020.4643","article-title":"Site specific and targeted therapy based on molecular profiling by next generation sequencing for cancer of unknown primary site","volume":"6","author":"Hayashi","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2025.07.007_bib35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","article-title":"Quantifying the expanding landscape of clinical actionability for patients with cancer","volume":"14","author":"Suehnholz","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2025.07.007_bib36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5644\/ama2006-124.392","article-title":"Tumor-type agnostic, targeted therapies; BRAF inhibitors join the group","volume":"51","author":"Vranic","year":"2022","journal-title":"Acta Med Acad"},{"key":"10.1016\/j.annonc.2025.07.007_bib37","unstructured":"Tumor-agnostic drugs. American Cancer Society. Updated June 20, 2024. Available at Bit.ly\/4fRNg8r. Accessed March 15, 2025."},{"key":"10.1016\/j.annonc.2025.07.007_bib38","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.annonc.2021.11.009","article-title":"Open label phase 2 study of the efficacy of nivolumab for cancer of unknown primary","volume":"33","author":"Tanizaki","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.07.007_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004822","article-title":"Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial","volume":"10","author":"Raghav","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annonc.2025.07.007_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000347","article-title":"Phase 2 study of pembrolizumab in patients with advanced rare cancers","volume":"8","author":"Naing","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annonc.2025.07.007_bib41","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1200\/JCO.2012.43.3755","article-title":"Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon Research Institute","volume":"31","author":"Hainsworth","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.07.007_bib42","first-page":"112","article-title":"A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile","volume":"11","author":"Hainsworth","year":"2012","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.annonc.2025.07.007_bib43","doi-asserted-by":"crossref","first-page":"e893","DOI":"10.1016\/j.clgc.2018.03.001","article-title":"Renal cell carcinoma presenting as carcinoma of unknown primary site: recognition of a treatable patient subset","volume":"16","author":"Greco","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2025.07.007_bib44","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.annonc.2022.11.013","article-title":"Cancer of unknown primary. ESMO clinical practice guidelines for diagnosis, treatment, and follow-up","volume":"34","author":"Kramer","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.07.007_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102882","article-title":"New rising entities in cancer of unknown primary: is there a real therapeutic benefit?","volume":"147","author":"Rassy","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.annonc.2025.07.007_bib46","series-title":"Cancer: Principles and Practice of Oncology","first-page":"1720","article-title":"Cancer of unknown primary site","author":"Greco","year":"2015"},{"key":"10.1016\/j.annonc.2025.07.007_bib47","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40801-016-0064-7","article-title":"Lung adenocarcinoma with anaplastic lymphoma kinase rearrangement presenting as carcinoma of unknown primary site: recognition and treatment implications","volume":"3","author":"Hainsworth","year":"2016","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.annonc.2025.07.007_bib48","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10147-013-0583-0","article-title":"Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset","volume":"19","author":"Varadhachary","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.07.007_bib49","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S1470-2045(24)00313-9","article-title":"Site-specific therapy guided by the 90-gene expression assay versus empiric chemotherapy in patients with cancer of unknown primary (Fudan CUP-001)","volume":"25","author":"Liu","year":"2024","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2025.07.007_bib50","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S1470-2045(24)00344-9","article-title":"Molecular diagnosis and site-specific therapy in cancer of unknown primary: an important milestone","volume":"25","author":"Greco","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2025.07.007_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115447","article-title":"Molecularly directed therapy in cancers of unknown primary: a systematic review and meta-analysis","volume":"222","author":"Labaki","year":"2025","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.annonc.2025.07.007_bib52","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1056\/NEJMc0707000","article-title":"Effect of CT on false positive diagnosis of appendicitis","volume":"358","author":"Sayre","year":"2008","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.annonc.2025.07.007_bib53","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1553-2712.2000.tb00470.x","article-title":"False-negative and false-positive errors in abdominal pain evaluation: failure to diagnose acute appendicitis and unnecessary surgery","volume":"7","author":"Graff","year":"2000","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.annonc.2025.07.007_bib54","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.18.00771","article-title":"Randomized phase 2 trial comparing site specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site","volume":"37","author":"Hayashi","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.07.007_bib55","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1093\/annonc\/mdz394","article-title":"A randomized phase 3 trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of unknown primary (CUP) site (GEFCAPI 04)","volume":"30","author":"Fizazi","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.07.007_bib56","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(24)00814-6","article-title":"Molecularly guided therapy versus chemotherapy after disease control in unfavorable cancer of unknown primary (CUPISCO): an open-label randomized phase II study","volume":"404","author":"Kramer","year":"2024","journal-title":"Lancet"},{"issue":"10452","key":"10.1016\/j.annonc.2025.07.007_bib57","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0140-6736(24)00975-9","article-title":"Molecular guided therapies: a practice-changing step forward in cancer of unknown primary management","volume":"4044","author":"Rassy","year":"2024","journal-title":"Lancet"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425008567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425008567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:25:14Z","timestamp":1793496314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425008567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0923753425008567"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.07.007","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer of unknown primary site and TNM staging: a new paradigm for patient management","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}